서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 34 of 34

Issue DateTitle / Author(s) / CitationFileAltmetrics
2009
Kinase Mutations and Efficacy of Imatinib in Korean Patients with Advanced Gastrointestinal Stromal Tumors
DOI
2009-04
A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor
DOI
2010-11
Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
view fileDOI
2012-04
Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study
DOI
2013-01
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation
DOI
2013-02
Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation (vol 71, pg 43, 2013)
DOI
2017-04
Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of lmatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
DOI
2017-06
Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach
DOI
2017-10
Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review
DOI
2017-12
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
DOI
2018-05
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
DOI
2018-07
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial
DOI
2018-09
Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG)
DOI
2019-02
Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design
DOI
2019-03
Korean practice guideline for gastric cancer 2018: An evidence-based, multi-disciplinary approach
DOI
2020-01
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
DOI
2020-05
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
DOI
2020-06
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer
DOI
2020-08
S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial
DOI
2021-03
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
DOI
2021-07
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
DOI
2021-09
Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)
DOI
2022-01
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
DOI
2022-01
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
DOI
2022-02
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
DOI
2022-05
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)
DOI
2023-02
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
DOI
2023-08
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
DOI
2023-11
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
DOI
2024-05
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Kitagawa, Yuko; Matsuda, Satoru; Gotoda, Takuji; Kato, Ken; Wijnhoven, Bas; Lordick, Florian; Bhandari, Pradeep; Kawakubo, Hirofumi; Kodera, Yasuhiro; Terashima, Masanori; Muro, Kei; Takeuchi, Hiroya; Mansfield, Paul F.; Kurokawa, Yukinori; So, Jimmy; Monig, Stefan Paul; Shitara, Kohei; Rha, Sun Young; Janjigian, Yelena; Takahari, Daisuke; Chau, Ian; Sharma, Prateek; Ji, Jiafu; de Manzoni, Giovanni; Nilsson, Magnus; Kassab, Paulo; Hofstetter, Wayne L.; Smyth, Elizabeth Catherine; Lorenzen, Sylvie; Doki, Yuichiro; Law, Simon; Oh, Do-Youn; Ho, Khek Yu; Koike, Tomoyuki; Shen, Lin; van Hillegersberg, Richard; Kawakami, Hisato; Xu, Rui-Hua; Wainberg, Zev; Yahagi, Naohisa; Lee, Yeong Yeh; Singh, Rajvinder; Ryu, Min-Hee; Ishihara, Ryu; Xiao, Zili; Kusano, Chika; Grabsch, Heike Irmgard; Hara, Hiroki; Mukaisho, Ken-ichi; Makino, Tomoki; Kanda, Mitsuro; Booka, Eisuke; Suzuki, Sho; Hatta, Waku; Kato, Motohiko; Maekawa, Akira; Kawazoe, Akihito; Yamamoto, Shun; Nakayama, Izuma; Narita, Yukiya; Yang, Han-Kwang; Yoshida, Masahiro; Sano, Takeshi

Gastric Cancer, Vol.27 No.3, pp.401-425

DOI
2024-07
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
DOI
2024-08
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
DOI
2024-10
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
DOI
2024-11
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
DOI
1